Estrogen induces apoptosis in estrogen deprivation-resistant breast cancer through stress responses as identified by global gene expression across time

Proceedings of the National Academy of Sciences of the United States of America

Volumn 108, Issue 47, 2011, Pages 18879-18886

  Ariazi, Eric A ^a   Cunliffe, Heather E ^b   Lewis Wambi, Joan S ^a   Slifker, Michael J ^a   Willis, Amanda L ^b,d   Ramos, Pilar ^b   Tapia, Coya ^b,e   Kim, Helen R ^a,c   Yerrum, Smitha ^a,f   Sharma, Catherine G N ^a   Nicolas, Emmanuelle ^a   Balagurunathan, Yoganand ^b   Ross, Eric A ^a   Jordan, V Craig ^a,c  

^a FOX CHASE CANCER CENTER   (United States)

^b TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^c GEORGETOWN UNIVERSITY   (United States)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^e UNIVERSITY HOSPITAL BASEL   (Switzerland)

^f VAN ANDEL RESEARCH INSTITUTE   (United States)

Author keywords

Antihormonal resistance; Aromatase inhibitor; Estrogen receptor; Gene expression microarrays; Selective estrogen receptor modulator

Indexed keywords

ARACHIDONIC ACID; BIM PROTEIN; CASPASE 4; CYTOKINE; ESTRADIOL; INTERFERON; INTERLEUKIN 17; INTERLEUKIN 4 RECEPTOR; INTERLEUKIN 6 RECEPTOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE;

APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CELL STRAIN MCF 7; CONTROLLED STUDY; ENDOPLASMIC RETICULUM STRESS; FATTY ACID SYNTHESIS; GENE EXPRESSION; HUMAN; HUMAN CELL; MOLECULAR INTERACTION; PRIORITY JOURNAL; PROTEIN FOLDING; PROTEIN PROCESSING; SIGNAL TRANSDUCTION; STRESS; UPREGULATION;

APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; ARACHIDONIC ACID; AREA UNDER CURVE; BREAST NEOPLASMS; CASPASES, INITIATOR; CELL LINE, TUMOR; ENDOPLASMIC RETICULUM STRESS; ESTRADIOL; FATTY ACIDS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MEMBRANE PROTEINS; MICROARRAY ANALYSIS; PROTEIN FOLDING; PROTO-ONCOGENE PROTEINS;

EID: 82755168809     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1115188108     Document Type: Article

References (37)

1. Dodds EC, Goldberg L, Lawson W, Robinson R (1938) Estrogenic activity of certain synthetic compounds. Nature 141:247-248.
2. Robson JM, Schönberg A (1937) Oestrous reactions including mating produced by triphenylethylene. Nature 140:196.
3. Haddow A, Watkinson JM, Paterson E, Koller PC (1944) Influence of synthetic oestrogens on advanced malignant disease. Br Med J 2:393-398.
4. Haddow A (1970) David A. Karnofsky memorial lecture. Thoughts on chemical therapy. Cancer 26:737-754.
5. Lerner LJ, Jordan VC (1990) Development of antiestrogens and their use in breast cancer: Eighth Cain memorial award lecture. Cancer Res 50:4177-4189. (Pubitemid 20225648)
6. Jordan VC (2003) Tamoxifen: A most unlikely pioneering medicine. Nat Rev Drug Discov 2:205-213.
7. Jordan VC (2008) Tamoxifen: Catalyst for the change to targeted therapy. Eur J Cancer 44:30-38.
8. Jordan VC (2001) Selective estrogen receptor modulation: A personal perspective. Cancer Res 61:5683-5687.
9. Jordan VC, Phelps E, Lindgren JU (1987) Effects of anti-estrogens on bone in castrated and intact female rats. Breast Cancer Res Treat 10:31-35. (Pubitemid 18038542)
10. Cummings SR, et al. (1999) The effect of raloxifene on risk of breast cancer in postmenopausal women: Results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 281:2189-2197. (Pubitemid 29275701)
11. Vogel VG, et al. (2006) Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 295:2727-2741.
12. Early Breast Cancer Trialists' Collaborative Group (1998) Tamoxifen for early breast cancer: An overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 351:1451-1467.
13. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365:1687-1717.
14. Berry DA, et al. (2006) Modeling the impact of treatment and screening on U.S. breast cancer mortality: A Bayesian approach. J Natl Cancer Inst Monogr 36:30-36.
15. Dowsett M, et al. (2010) Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 28:509-518.
16. Osborne CK, Coronado EB, Robinson JP (1987) Human breast cancer in the athymic nude mouse: Cytostatic effects of long-term antiestrogen therapy. Eur J Cancer Clin Oncol 23:1189-1196. (Pubitemid 17112483)
17. Gottardis MM, Jordan VC (1988) Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. Cancer Res 48:5183-5187.
18. Wolf DM, Jordan VC (1993) A laboratory model to explain the survival advantage observed in patients taking adjuvant tamoxifen therapy. Recent Results Cancer Res 127:23-33.
19. Yao K, et al. (2000) Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice. Clin Cancer Res 6:2028-2036. (Pubitemid 30305102)
20. Jordan VC (2004) Selective estrogen receptor modulation: Concept and consequences in cancer. Cancer Cell 5:207-213.
21. Katzenellenbogen BS, Kendra KL, Norman MJ, Berthois Y (1987) Proliferation, hormonal responsiveness, and estrogen receptor content of MCF-7 human breast cancer cells grown in the short-term and long-term absence of estrogens. Cancer Res 47: 4355-4360. (Pubitemid 17128144)
22. Welshons WV, Jordan VC (1987) Adaptation of estrogen-dependent MCF-7 cells to low estrogen (phenol red-free) culture. Eur J Cancer Clin Oncol 23:1935-1939. (Pubitemid 18013337)
23. Song RX, et al. (2001) Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17beta-estradiol. J Natl Cancer Inst 93:1714-1723. (Pubitemid 33130260)
24. Lewis JS, et al. (2005) Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation. J Natl Cancer Inst 97:1746-1759. (Pubitemid 41782284)
25. Lewis-Wambi JS, et al. (2008) Buthionine sulfoximine sensitizes antihormone-resistant human breast cancer cells to estrogen-induced apoptosis. Breast Cancer Res 10:R104.
26. Lønning PE, et al. (2001) High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy. Breast Cancer Res Treat 67: 111-116. (Pubitemid 32744491)
27. Lønning PE (2009) Additive endocrine therapy for advanced breast cancer-back to the future. Acta Oncol 48:1092-1101.
28. Ellis MJ, et al. (2009) Lower-dose vs high-dose oral estradiol therapy of hormone receptor- positive, aromatase inhibitor-resistant advanced breast cancer: A phase 2 randomized study. JAMA 302:774-780.
29. Jiang SY, Wolf DM, Yingling JM, Chang C, Jordan VC (1992) An estrogen receptor positive MCF-7 clone that is resistant to antiestrogens and estradiol. Mol Cell Endocrinol 90:77-86.
30. Pink JJ, Jiang SY, Fritsch M, Jordan VC (1995) An estrogen-independent MCF-7 breast cancer cell line which contains a novel 80-kilodalton estrogen receptor-related protein. Cancer Res 55:2583-2590.
31. Pink JJ, Jordan VC (1996) Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines. Cancer Res 56:2321-2330. (Pubitemid 26154081)
32. Lewis JS, Osipo C, Meeke K, Jordan VC (2005) Estrogen-induced apoptosis in a breast cancer model resistant to long-term estrogen withdrawal. J Steroid Biochem Mol Biol 94:131-141. (Pubitemid 40614526)
33. Lewis-Wambi JS, Cunliffe HE, Kim HR, Willis AL, Jordan VC (2008) Overexpression of CEACAM6 promotes migration and invasion of oestrogen-deprived breast cancer cells. Eur J Cancer 44:1770-1779.
34. Hu ZZ, et al. (2011) Proteomic analysis of pathways involved in estrogen-induced growth and apoptosis of breast cancer cells. PLoS One 6:e20410.
35. Levenson AS, Jordan VC (1997) MCF-7: The first hormone-responsive breast cancer cell line. Cancer Res 57:3071-3078. (Pubitemid 27351713)
36. Liu H, et al. (2003) Apoptotic action of 17beta-estradiol in raloxifene-resistant MCF-7 cells in vitro and in vivo. J Natl Cancer Inst 95:1586-1597. (Pubitemid 37455926)
37. Chisamore MJ, Ahmed Y, Bentrem DJ, Jordan VC, Tonetti DA (2001) Novel antitumor effect of estradiol in athymic mice injected with a T47D breast cancer cell line overexpressing protein kinase Calpha. Clin Cancer Res 7:3156-3165. (Pubitemid 32963839)